Idorsia Ltd (SWX:IDIA)
1.033
-0.041 (-3.82%)
Apr 3, 2025, 5:31 PM CET
Idorsia Revenue
In the year 2024, Idorsia had annual revenue of 112.51M CHF, down -26.17%. Idorsia had revenue of 59.90M in the quarter ending December 31, 2024, with 178.42% growth.
Revenue
112.51M
Revenue Growth
-26.17%
P/S Ratio
1.68
Revenue / Employee
173.09K
Employees
650
Market Cap
231.69M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 112.51M | -39.88M | -26.17% |
Dec 31, 2023 | 152.39M | 55.28M | 56.93% |
Dec 31, 2022 | 97.10M | 61.75M | 174.70% |
Dec 31, 2021 | 35.35M | -36.41M | -50.74% |
Dec 31, 2020 | 71.76M | 47.94M | 201.26% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Roche Holding AG | 62.40B |
Novartis AG | 46.87B |
Alcon | 8.98B |
Lonza Group AG | 6.57B |
Galderma Group AG | 4.02B |
Straumann Holding AG | 2.50B |
Sandoz Group AG | 9.41B |
Sonova Holding AG | 3.71B |
Idorsia News
- 7 days ago - Idorsia publishes its Annual Report 2024 - GlobeNewsWire
- 20 days ago - Idorsia announces the publication of positive data with daridorexant in patients with chronic insomnia and nocturia - GlobeNewsWire
- 4 weeks ago - Idorsia Ltd (IDRSF) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Idorsia Ltd 2024 Q4 - Results - Earnings Call Presentation - Seeking Alpha
- 4 weeks ago - Idorsia announces financial results for 2024 - GlobeNewsWire
- 5 weeks ago - Invitation to Idorsia's Full Year 2024 Financial Reporting webcast and conference call - GlobeNewsWire
- 5 weeks ago - Idorsia reaches an agreement with significant bondholders to restructure its convertible bond debt and to secure funding for future operations - GlobeNewsWire
- 5 weeks ago - Idorsia is released from exclusivity constraint regarding the global rights to aprocitentan – now pivoting to alternative parties - GlobeNewsWire